Cooperative Dual-Activity Targeted Nanomedicine for Specific and Effective Prostate Cancer Therapy

Yang, Hung-Wei; Hua, Mu-Yi; Liu, Hao-Li; Tsai, Rung-Ywan; Chuang, Cheng-Keng; Chu, Po-Chun; Wu, Pei-Shan; Chang, Ying-Hsu; Chuang, Heng-Chang; Yu, Kai-Jie; Pang, See‐Tong

doi:10.1021/nn2048526

Cited by 53 publications

(38 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several kinds of nanoparticle systems for prostate cancer diagnosis and therapy424344 have previously been developed to improve the efficacy of specific delivery and to decrease the incidence of serious side effects. However, in all cases, nanoparticles are used to act as the carrier for other chemotherapy drugs.…”

Section: Discussionmentioning

confidence: 99%

Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment

et al. 2017

View full text Add to dashboard Cite

High global incidence of prostate cancer has led to a focus on prevention and treatment strategies to reduce the impact of this disease in public health. Boron compounds are increasingly recognized as preventative and chemotherapeutic agents. However, systemic administration of soluble boron compounds is hampered by their short half-life and low effectiveness. Here we report on hollow boron nitride (BN) spheres with controlled crystallinity and boron release that decrease cell viability and increase prostate cancer cell apoptosis. In vivo experiments on subcutaneous tumour mouse models treated with BN spheres demonstrated significant suppression of tumour growth. An orthotopic tumour growth model was also utilized and further confirmed the in vivo anti-cancer efficacy of BN spheres. Moreover, the administration of hollow BN spheres with paclitaxel leads to synergetic effects in the suppression of tumour growth. The work demonstrates that hollow BN spheres may function as a new agent for prostate cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment

et al. 2017

View full text Add to dashboard Cite

show abstract

“…We took advantage of the interactions between the hydrophobic inner layer of IONPs and hydrophobic drug PTX. [45][46][47] The PTX encapsulation in biodegradable, nontoxic, nanoscale drug delivery systems is very useful for drug delivery because this type of system can protect PTX from degradation during circulation. This characteristic lowers the toxicity of PTX by increasing drug circulation time, showing significant pharmacokinetic efficiency and better patient outcome.…”

Section: Efficiency Of Ptx Encapsulationmentioning

confidence: 99%

Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer

Ahmed¹,

Salam²,

Yates³

et al. 2017

IJN

View full text Add to dashboard Cite

As an alternative therapeutic treatment to reduce or eliminate the current side effects associated with advanced prostate cancer (PCa) chemotherapy, a multifunctional double-receptor-targeting iron oxide nanoparticles (IONPs) (luteinizing hormone-releasing hormone receptor [LHRH-R] peptide- and urokinase-type plasminogen activator receptor [uPAR] peptide-targeted iron oxide nanoparticles, LHRH-AE105-IONPs) drug delivery system was developed. Two tumor-targeting peptides guided this double-receptor-targeting nanoscale drug delivery system. These peptides targeted the LHRH-R and the uPAR on PCa cells. Dynamic light scattering showed an increase in the hydrodynamic size of the LHRH-AE105-IONPs in comparison to the non-targeted iron oxide nanoparticles (NT-IONPs). Surface analysis showed that there was a decrease in the zeta potential values for drug-loaded LHRH-AE105-IONPs compared to the NT-IONPs. Prussian blue staining demonstrated that the LHRH-AE105-IONPs were internalized efficiently by the human PCa cell line, PC-3. In vitro, magnetic resonance imaging (MRI) results confirmed the preferential binding and accumulation of LHRH-AE105-IONPs in PC-3 cells compared to normal prostate epithelial cells (RC77N/E). The results also showed that LHRH-AE105-IONPs significantly maintained T 2 MRI contrast effects and reduced T 2 values upon internalization by PC-3 cells. These paclitaxel-loaded double-receptor-targeting IONPs also showed an approximately twofold reduction in PC-3 cell viability compared to NT-IONPs.

show abstract

“…On the basis of the above results, upregulation of PSMA involving CTE‐truncated mutated AR may explain the escape of prostate cancer cells to androgen deprivation therapy. These features support the concept to make it one of the most promising biomarkers in the diagnosis and treatment of prostate cancer (Liu et al, ; Yang et al, ). Androgen dependence of prostate epithelium in vivo requires paracrine activity of stromal AR, similar to the requirement for mesenchymal AR in epithelial–mesenchymal interactions during early prostate organogenesis (Abate‐Shen and Shen, ).…”

Section: Discussionmentioning

confidence: 99%

A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells

Jemaa

Sallami

Céraline

et al. 2013

Cell Biology International

View full text Add to dashboard Cite

We have investigated the expression of prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA) transcripts in androgen-dependent (LNCaP) and androgen-independent (22Rv1) prostate cancer cell lines. We also enquired whether Q640X CTE-truncated androgen receptor (AR) has an impact on transcription of mRNA for PSMA and PSA in transfected androgen-sensitive prostate cancer LNCaP cells. Wild type LNCaP, 22Rv1 prostate cancer cells, prostate stromal cells (PrSC) and LNCaP cells transfected with p-Q640X AR, p-WT AR or p-C3 empty plasmids were studied. The expression of PSMA and PSA were detected by real-time PCR after transfection for 4 and 7 days. Expression of mRNAs for PSA was sixfold greater than PSMA in wild type LNCaP cells. In contrast, the wild type androgen refractory 22Rv1 cell line reacted almost exactly the opposite way reverse to LNCaP cells, since the transcription of mRNA for PSMA almost twofold greater than PSA. Non-transfected human PrSC responded similarly to PSMA mRNA and PSA mRNA was not detected in these cells. Q640X AR transfected LNCaP cells downregulated the expression of PSMA and PSA genes after 7 days. Our results demonstrate that Q640X mutated AR may have an important regulatory role in mediating the PSMA and PSA genes expression during the progression of prostate cancer from androgen-dependence to androgen-independence. Understanding their functional properties and mechanisms by which ARs involved in regulation of PSMA and PSA expression will allow the identification of new target therapies for the treatment of hormone-resistant prostate cancer.

show abstract

Cooperative Dual-Activity Targeted Nanomedicine for Specific and Effective Prostate Cancer Therapy

Cited by 53 publications

References 46 publications

Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment

Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment

Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer

A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells

Contact Info

Product

Resources

About